mononuclear phagocytes (14, 15) .
We found that monocytes from patients with either form of leprosy undergo activation in response to lymphokines and strongly inhibit L. pneumophila multiplication. However, specifically in response to M. leprae antigens, mononuclear cells from patients with lepromatous leprosy fail to release monocyte-activating cytokines. In contrast, mononuclear cells from patients with tuberculoid leprosy secrete such cytokines, which activate monocytes to inhibit the intracellular multiplication of L. pneumophila.
Materials and Methods
Patients. All patients were adults and were seen at the Rockefeller University Hospital (Table I ). The diagnosis of leprosy was supported in all cases by a skin biopsy examined by pathologists at the U. S. Public Health Service National Hansen's Disease Center, Carville, LA. Clinical diagnosis was based on the Ridley-Jopling classification scheme (1) . Informed written consent was obtained from all patients.
Media. Egg yolk buffer, with or without 1% bovine serum albumin, and RPMI 1640 medium were prepared or obtained as described previously (10) . No antibiotics were added to any medium in any of the experiments. Aga r. Modified charcoal yeast extract agar was prepared in 100 × 15-mm bacteriologic petri dishes as described (14) . Serum. Venous blood was obtained, clotted, and serum separated and stored at -70°C until used as described (16) . Normal (nonimmune) human serum (type AB) with an indirect fluorescent antibody (IFA) anti-L, pneumophila titer (17) of <1:64 was obtained from an adult donor not known to have ever had Legionnaires' disease. Bacteria. L. pneumophila, Philadelphia 1 strain, was grown in embryonated hens' eggs, harvested, tested for viability and for the presence of contaminating bacteria, stored at -70°C, and partially purified by differential centrifugation just before use, as described (14) . Human Blood Mononuclear Cells. Heparinized venous blood was obtained from patients and the blood mononuclear cell fraction was separated by centrifugation over a Ficollsodium diatrizoate solution as previously described (14) .
Preparation of Mononuclear Celt Supernatants.
A single large batch of Con A-induced mononuclear cell supernatant (Con A supernatant) and of supernatant control (Con A supernatant control) was prepared from the mononuclear cells of a single normal donor who did not have leprosy (13) . Con A supernatant was prepared by incubating donor mononuclear cells 6 (3 x 10/ml) in 2 ml RPMI medium containing 25% fresh normal human serum in plastic petri dishes with 15 #g/ml Con A for 2 d at 37°C in 5% CO2-95% air. This concentration of Con A and this incubation period yield a maximally potent Con A supernatant (12) . At the end of the incubation, the cultures were transferred to conical tubes and the cells were sedimented at 200 g for 10 min at 4°C. The supernatant was removed, filtered through 0.2 #m Millipore filters (Millipore Corp. Bedford, MA), and stored at -70°C. Con A supernatant control was prepared in the same way except that Con A was added at the end rather than at the beginning of the 2-d incubation period.
Con A supernatants and supernatant controls were prepared from patients with leprosy in the same way except that cells were cultured in 16-mm tissue culture wells (Linbro, 24-well plates; Flow Laboratories, Inc., McLean, VA) containing 500 #1 of medium; cell and reagent concentrations were the same as in the above paragraph.
M. leprae supernatants were prepared from patients in the same way and at the same time as Con A supernatants except that 100 ttl of partially purified, armadillo-derived, freeze-dried M. leprae was used instead of Con A, and mononuclear cells were cultured BT, borderline tuberculoid leprosy; TT, tuberculoid leprosy. Two patients (C and M) had erythema nodosum leprosum at the time of the study. One patient (C) was on steroids at the time of the study. None of the patients were lymphopenic at the time of the study. * Lived in endemic area (Brazil) prior to illness.
with the M. leprae antigen for 5 d instead of 2 d. M. leprae supernatant controls were prepared in the same way except that M. leprae antigen was added at the end rather than at the beginning of the 5-d incubation period. In another study (13) , patient mononuclear cell responses to this M, leprae antigen were shown to be relatively specific in both of the assays used in this study. In both the mononuclear cell thymidine incorporation assay and the assay for monocyte-activating cytokines, mononuclear cells from patients recovered from Legionnaires' disease responded more strongly to L. pneumophila antigens than to M. leprae antigens whereas mononuclear cells from patients with tuberculoid leprosy responded more strongly to M. leprae than to L. pneumophila antigens (13) . The M. leprae antigen was kindly provided by the Immunology of Leprosy Unit (IMMLEP), World Health Organization, Geneva, Switzerland.
The sediments remaining after the removal of supernatants were all tested for the presence of contaminating microorganisms by resuspending them in RPMI medium and culturing aliquots of the suspension on 5% sheep blood tryptic soy broth agar; none of the preparations used in this study were contaminated.
Activation of Patient
Monocytes. Patient monocytes were tested for their capacity to be activated by Con A-induced cytokines generated by normal mononuclear cells. Activation was assayed by measuring the capacity of the cytokine-treated monocytes to inhibit the intracellular multiplication of L. pneumophila (12, 13) . Freshly explanted patient mononuclear cells (1.5 × 106) were incubated in 16-mm tissue culture wells in 500 #1 RPMI 1640 medium containing 10% fresh normal human serum for 1.5 h at 37°C in 5% CO2-95% air to allow monocytes to adhere. The culture wells were then vigorously washed to remove the nonadherent leukocytes. The monocyte monolayers were then incubated for 24 h in 500 #1 RPMI medium containing 20% fresh serum and 30% (vol/vol) Con A supernatant or supernatant control prepared as described above. After 24 h, virulent egg yolk-grown L. pneumophila (5 × 10~colony-forming units (CFU)/ml) were added to the cultures. The cultures were incubated at 37°C in 5% CO2-95% air on a gyratory shaker for 1 h and under stationary conditions thereafter. CFU of L. pneumophila in each culture were determined daily on charcoal yeast extract agar as described (14) . All cultures were prepared and tested in triplicate.
Activation of Normal Monocytes by Supernatants Derived from Patients with Leprosy.
Mononuclear cells from a single adult donor were used in all experiments; the donor had no history of Legionnaires' disease and had a serum IFA anti-L, pneumophila titer of <1:64. Monocyte monolayers were prepared in 16-mm tissue culture wells as described in the previous assay and incubated for 24 h in 500 ~i RPMI 1640 medium containing 20% fresh normal human serum and 30% (vol/vol) Con A supernatant, Con A supernatant control, M. leprae supernatant, or M. leprae supernatant control generated from the mononuclear cells of patients, as described above. After 24 h, the cultures were infected with L. pneumophila and cultured daily for CFU/ml as described in the previous assay. All cultures were prepared and tested in duplicate. All supernatants from a given patient were tested at the same time. Two patients with lepromatous leprosy were tested at the same time as two patients with tuberculoid leprosy.
Thymidine Incorporation by Mononuclear Cells. The mononuclear cells remaining after the generation of Con A or M. leprae supernatants or supernatant controls were resus-7 pended in 600 #1 RPMI medium (~1 × 10 of the originally cultured mononuclear cells/ ml) as described (13) . Triplicate 50-IA aliquots of this cell suspension were added to microtest wells (Falcon, 96-well tissue culture plate; Becton, Dickinson & Co., Oxnard, CA) and mixed with an equal volume of RPMI containing 2% serum and 5.0 #Ci [SH]-thymidine/ml. The cells were incubated for 2 h at 37°C in 5% CO2-95% air, and harvested on glass fiber filter paper (Whatman, Inc., Clifton, NJ) with a cell harvester. The filters were dried, placed in glass vials containing liquid scintillation-counting solution (Hydrofluor; National Diagnostics, Inc., Somerville, NJ), incubated overnight at 4°C, and counts per minute registered with a liquid scintillation counter (Nuclear Chicago Corp., Subsidiary of G. D. Searle and Co., Des Plaines, IL).
by Con A supernatant ( Fig. 1 and Table II ) and they strongly inhibited L.
pneumophila multiplication in comparison to monocytes pretreated with Con A supernatant control. The degree of inhibition was comparable in both groups.
L. pneumophila multiplication was decreased by a mean of 2.03 logs by activated monocytes from patients with lepromatous leprosy and by a mean of 1.81 logs by activated monocytes from patients with tuberculoid leprosy (Table II) (difference not significant). The degree of inhibition by activated monocytes from either group of patients was not significantly different from that of activated monocytes from normal persons (mean 2.04 logs; Table II pneumophila (2.5 × 10 s CFU/ml) and CFU/ml was determined daily. Each point represents the mean CFU/ml for three replicate tissue culture wells + SEM. Fig. 1 . CFU/ml were determined daily. Data presented are CFU/ ml at the peak of infection, i.e., when CFU/ml in control cultures reached their highest level (2 or 3 d after infection). Data are the mean CFU/ml for three replicate tissue culture wells _ SEM. Monocytes from three normal persons activated by the same batch of Con A supernatant used throughout this study inhibited L. pneumophila multiplication by a mean of 2.04 + 0.40 logs. This degree of inhibition was not significantly different from that of activated monocytes from either group of patients. * Log inhibition = (log CFU/ml in monocyte cultures treated with supernatant control) -(log CFU/ ml in monocyte cultures treated with supernatant). *P> 0.5.
We next studied [~H]thymidine incorporation in response to M. leprae antigens and Con A of mononuclear cells from patients with lepromatous and tuberculoid leprosy (Table III) 
Mononuclear Cells from Patients with Lepromatous Leprosy Fail to Generate Monocyteactivating Cytokines in Response to M. leprae.
We assayed the mononuclear cells of patients with lepromatous and tuberculoid leprosy for their capacity to generate monocyte-activating cytokines in response to Con A and M. leprae. To do this, we prepared Con A and M. leprae supernatants and supernatant controls from the mononuclear cells of patients with leprosy as described in Materials and Methods. We then tested the capacity of these preparations to activate monocytes by treating normal monocytes with each preparation and measuring monocyte capacity to inhibit the intracellular multiplication of L. pneumophila (Table IV) .
The various supernatant preparations were obtained from the same mononuclear cell cultures used to study proliferative responses to Con A and M. leprae in Table III .
Mononuclear cells from patients with both lepromatous and tuberculoid leprosy responded to Con A with the generation of monocyte-activating cytokines, although Con A-induced supernatants from patients with lepromatous leprosy were less potent than Con A-induced supernatants from the patients with tuberculoid leprosy. Supernatants from patients with lepromatous leprosy resulted in a mean inhibition of 0.87 logs in L. pneumophila multiplication while supernatants from patients with tuberculoid leprosy resulted in a mean inhibition of 1.61 logs.
Mononuclear cells from patients with tuberculoid leprosy, with one exception, also responded to M. leprae antigens with the production of monocyte-activating cytokines. M. leprae supernatants generated from the mononuclear cells of patients with tuberculoid leprosy resulted in a mean inhibition of 0.69 logs. This degree of inhibition is comparable to that resulting from treatment of normal monocytes with L. pneumophila-induced supernatants generated from the mononuclear cells of patients recovered from Legionnaires' disease (13 lepromatous leprosy to generate monocyte-activating cytokines generally parallels their capacity to incorporate thymidine in response to Con A and M. leprae.
Discussion
We have found that monocytes from patients with either lepromatous or tuberculoid leprosy can be activated normally, as measured by a highly relevant assay: the capacity of these monocytes to inhibit the multiplication of another activated. This finding therefore supports the hypothesis that the defect in cellmediated immunity in lepromatous leprosy derives from a failure to activate mononuclear phagocytes rather than from an intrinsic inability of these cells to be activated. This hypothesis does not exclude the possibility that mononuclear phagocytes located at the site of infection are somehow inhibited from being activated. Drutz et al. (19) previously reported that nonactivated human monocytes from patients with iepromatous and tuberculoid leprosy have comparable capacities to kill a variety of microorganisms (19) Although mononuclear phatocytes must generally be activated to control infection by intracellular pathogens, this study by Drutz et al. further supports the hypothesis that circulating mononuclear phagocytes from patients with lepromatous leprosy have a normal antimicrobial capacity.
We have also found that mononuclear cells from patients with lepromatous and tuberculoid leprosy respond to Con A with [SH]thymidine incorporation and with the production of monocyte-activating cytokines whereas only mononuclear cells from patients with tuberculoid leprosy respond in these ways to M. leprae.
These findings suggest that mononuclear cells of patients with lepromatous leprosy have a normal capacity to generate monocyte-activating cytokines but that they fail to do so in response to M. leprae. Alternatively, it is possible that mononuclear cells of patients with lepromatous leprosy, in response to M. leprae, generate substances inhibitory to monocyte activation at the same time as they generate monocyte-activating cytokines. However, this seems less likely in view of the fact that these mononuclear cells also fail to proliferate in response to M.
leprae. These findings thus support the hypothesis that the defect in cell-mediated immunity in patients with lepromatous leprosy derives from a failure to generate, in response to M. leprae but not other antigens, cytokines necessary to activate mononuclear phagocytes. If this is so, then the underlying basis for this profound defect in cytokine production is obscure, although suppressor cells or factors have been suggested as playing a role (20, 21) . Consistent with a suppressor mechanism, Van Voorhis et al. (22) have recently reported from this laboratory that the T cell population in skin lesions of patients with lepromatous leprosy is devoid of OKT4/Leu 3a-positive (helper) cells and is comprised almost exclusively of OKT8/Leu 2a-positive (suppressor) cells. In contrast, the T cell population in skin lesions of patients with tuberculoid leprosy is comprised predominantly of OKT4/Leu 3a-positive cells (22) . Similarly, Modlin et al. (23) have reported that the T cell helper/suppressor ratio in two patients with uncomplicated lepromatous leprosy was lower than in four patients with tuberculoid leprosy. More recent studies indicate that peripheral blood mononuclear cells from patients with lepromatous leprosy fail to produce interleukin 2 or gamma interferon in response to M. leprae.
Summary
We have examined the capacity of monocytes from patients with leprosy to undergo activation and the capacity of mononuclear cells from these patients to incorporate [3H]thymidine and produce monocyte-activating cytokines.
Monocytes from patients with either lepromatous or tuberculoid leprosy were activated by concanavalin A (Con A)-induced mononuclear cell supernatants generated from the leukocytes of a normal person. Monocytes activated by these supernatants strongly inhibited L. pneumophila multiplication, and the degree of inhibition was comparable in both groups of patients.
Mononuclear cells from patients with either form of leprosy responded comparably to Con A with vigorous [~H]thymidine incorporation. Mononuclear cells from patients with tuberculoid leprosy also vigorously incorporated [3H]thymidine in response to M. Ieprae antigens. In contrast, mononuclear cells from patients with lepromatous leprosy did not exhibit significant [3H]thymidine incorporation in response to M. leprae antigens.
The capacity of mononuclear cells to generate monocyte-activating cytokines generally paralleled their capacity to incorporate [3H]thymidine in response to Con A and M. leprae. Mononuclear cells from patients with either form of leprosy responded to Con A with the production of cytokines (supernatants) able to activate normal monocytes, expressed by inhibition of L. pneumophila multiplication. However Con A-induced supernatants from patients with lepromatous leprosy were less potent than Con A-induced supernatants from patients with tuberculoid leprosy. Mononuclear cells from patients with tuberculoid leprosy responded to M. leprae antigens with the production of potent monocyte-activating supernatants. In contrast, mononuclear cells from patients with lepromatous leprosy did not produce monocyte-activating cytokines in response to M. leprae antigens.
These studies support the hypothesis that the immunological defect in lepromatous leprosy results from a failure to activate mononuclear phagocytes rather than from an intrinsic inability of these cells to be activated. We suggest that the failure to activate mononuclear phagocytes stems from defective production of monocyte-activating cytokines in response to M. leprae antigens.
